Clean deal. Trading tightish at 2.7%/10% gross/annualised spread, assuming early June completion. If in, stay in. If small, illiquid arbs are your bent, look to enter here and on any weakness.
What is covered in the Full Insight:
Introduction to Scheme Implementation Deed
Details of Cosette Pharmaceuticals' Offer
Shareholder and Regulatory Support
Market Implications and Trading Strategy
Fundamentals and Share Performance of Mayne Pharma
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.